Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/2
165
about 4.9 years
18+
3 sites in MI, TX, UT
What this study is about
This trial is testing a treatment called GTAEXS617 for people with advanced solid tumors. The goal is to see if the treatment is safe and effective.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take GTAEXS617
- 2.Take SoC
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Primary: Number of Participants With Treatment Emergent Adverse Events (TEAEs), Phase 2 : Objective Response Rate (ORR) as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1
Secondary: Disease Control Rate (DCR), Duration of Response (DOR), Maximum Plasma Concentration (Cmax) of GTAEXS617, Phase 1: ORR as Assessed by Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1, Progression-Free Survival (PFS), Time Maximum Plasma Concentration (Tmax) of GTAEXS617
Oncology